• Publications
  • Influence
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
TLDR
CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy, however, data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder is lacking.
Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.
TLDR
Results provide strong pharmacokinetic and biochemical evidence for activation of Nrf2 and phase II genes in the brain and also offer a neuroprotective strategy that may have clinical relevance for PD therapy.
Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration
TLDR
Older Pink1−/− mice show increasing mitochondrial dysfunction resulting in impaired neural activity similar to PD, in absence of overt neuronal death.
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
TLDR
It is shown that CB(2) cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients, support a pivotal role for CB( 2) receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington’s disease as well as in other Neurodegenerative disorders with a significant excitotoxic component.
Presence of cannabinoid binding sites in the brain from early postnatal ages.
TLDR
The present study demonstrates the presence of cannabinoid receptors in the brain from early postnatal ages, exhibiting a progressive increase which maximised on days 30 or 40 and then subsequently decreased to adult values.
...
...